GSK, Human Genome Sciences' lupus drug Benlysta wins European approval
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline and Human Genome Sciences have won approval in Europe to market Benlysta (belimumab) for the treatment of lupus patients with a high degree of disease activity.